Roxanne Saucier1, Daniel Wolfe1, Nabarun Dasgupta2. 1. Open Society Foundations, New York, NY, USA. 2. University of North Carolina at Chapel Hill, Suite 500, CB 7505, 137 E. Franklin St., Chapel Hill, NC, 27599, USA. nabarund@unc.edu.
Abstract
INTRODUCTION: An extended-release injectable naltrexone suspension (Vivitrol®) was approved in USA in 2010 for the prevention of relapse to opioid dependence. Concerns, raised at the time of approval, about rebound overdose risk following the last dose, have not been adequately studied. We sought to determine the time period of concern for fatal overdose associated with Vivitrol. METHODS: We performed a retrospective case review of Vivitrol spontaneous reports (October 2010-March 2016) in the US Food and Drug Administration Adverse Event Reporting System via the Freedom of Information Act. Case narratives were manually reviewed to identify overdose deaths amongst current and former patients, extracting information on the time from discontinuation, followed by causality assessment. RESULTS: Narratives on 263 deaths and overdose-related outcomes were obtained. One hundred and forty-five death reports were assessed for causality. Among these reports, cause of death was unknown in 46%, while 52 fatal overdoses met the case definition. Of 52 overdoses, time between the last dose and death was known for 28; 22 (84.6%) occurred within 2 months of the last Vivitrol injection [median 46 days (interquartile range 29.5-82)]. The sponsor's causality assessment in 75% of fatal overdoses repeated verbatim text that placed responsibility on underlying opioid dependence and precluded a link between medication and overdose or ignored rebound risk following treatment discontinuation. CONCLUSIONS: Vivitrol adverse event reports suggest the need to investigate two months following the last medicine injection as a period of particular concern for overdose. A registry study would best quantify risk. Providers should report suspected post-discontinuation overdoses to government authorities.
INTRODUCTION: An extended-release injectable naltrexone suspension (Vivitrol®) was approved in USA in 2010 for the prevention of relapse to opioid dependence. Concerns, raised at the time of approval, about rebound overdose risk following the last dose, have not been adequately studied. We sought to determine the time period of concern for fatal overdose associated with Vivitrol. METHODS: We performed a retrospective case review of Vivitrol spontaneous reports (October 2010-March 2016) in the US Food and Drug Administration Adverse Event Reporting System via the Freedom of Information Act. Case narratives were manually reviewed to identify overdose deaths amongst current and former patients, extracting information on the time from discontinuation, followed by causality assessment. RESULTS: Narratives on 263 deaths and overdose-related outcomes were obtained. One hundred and forty-five death reports were assessed for causality. Among these reports, cause of death was unknown in 46%, while 52 fatal overdoses met the case definition. Of 52 overdoses, time between the last dose and death was known for 28; 22 (84.6%) occurred within 2 months of the last Vivitrol injection [median 46 days (interquartile range 29.5-82)]. The sponsor's causality assessment in 75% of fatal overdoses repeated verbatim text that placed responsibility on underlying opioid dependence and precluded a link between medication and overdose or ignored rebound risk following treatment discontinuation. CONCLUSIONS:Vivitrol adverse event reports suggest the need to investigate two months following the last medicine injection as a period of particular concern for overdose. A registry study would best quantify risk. Providers should report suspected post-discontinuation overdoses to government authorities.
Authors: Daniel Wolfe; M Patrizia Carrieri; Nabarun Dasgupta; Alex Wodak; Robert Newman; R Douglas Bruce Journal: Lancet Date: 2011-04-30 Impact factor: 79.321
Authors: Evgeny Krupitsky; Edward V Nunes; Walter Ling; Ari Illeperuma; David R Gastfriend; Bernard L Silverman Journal: Lancet Date: 2011-04-30 Impact factor: 79.321
Authors: Evgeny Krupitsky; Edward V Nunes; Walter Ling; David R Gastfriend; Asli Memisoglu; Bernard L Silverman Journal: Addiction Date: 2013-05-24 Impact factor: 6.526
Authors: Elizabeth L C Merrall; Azar Kariminia; Ingrid A Binswanger; Michael S Hobbs; Michael Farrell; John Marsden; Sharon J Hutchinson; Sheila M Bird Journal: Addiction Date: 2010-06-23 Impact factor: 6.526
Authors: Joshua D Lee; Edward V Nunes; Patricia Novo; Jeanine May; Abigail Matthews; Paul Van Veldhuisen; Robert Lindblad; David Liu; John Rotrosen Journal: J Addict Med Date: 2022 Jul-Aug 01 Impact factor: 4.647
Authors: Louisa Degenhardt; Jason Grebely; Jack Stone; Matthew Hickman; Peter Vickerman; Brandon D L Marshall; Julie Bruneau; Frederick L Altice; Graeme Henderson; Afarin Rahimi-Movaghar; Sarah Larney Journal: Lancet Date: 2019-10-23 Impact factor: 79.321
Authors: Alexandria Macmadu; Joëlla W Adams; S E Bessey; Lauren Brinkley-Rubinstein; Rosemarie A Martin; Jennifer G Clarke; Traci C Green; Josiah D Rich; Brandon D L Marshall Journal: Int J Drug Policy Date: 2020-07-22
Authors: Jake R Morgan; Bruce R Schackman; Zoe M Weinstein; Alexander Y Walley; Benjamin P Linas Journal: Drug Alcohol Depend Date: 2019-05-03 Impact factor: 4.852
Authors: Bernard Silverman; Gary Bloomgren; Priya Jain; Kimberley Marcopul; Alexandra Silveira; James Fratantonio; Maria Sullivan; Sarah Akerman Journal: Drug Saf Date: 2018-10 Impact factor: 5.606
Authors: Priya Jain; Kimberley McKinnell; Rose Marino; Prashanthi Vunnava; Marie A Liles-Burden; Avani Desai; Madé Wenten; James Fratantonio; Sarah C Akerman; Maria A Sullivan; Gary Bloomgren Journal: Drug Saf Date: 2020-11-30 Impact factor: 5.606